UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Long‐term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52‐week outcomes from the DEPICT‐1 and ‐2 studies

Diabetes, obesity & metabolism, 2021-02, Vol.23 (2), p.549-560

2021

Volltextzugriff (PDF)

Potential mechanisms responsible for cardioprotective effects of sodium-glucose co-transporter 2 inhibitors

Cardiovascular diabetology, 2018-07, Vol.17 (1), p.101-101, Article 101

2018

Volltextzugriff (PDF)

Real-world evaluation of glucose-lowering therapies and the use of weight-adjusted variable rate intravenous insulin infusion in the management of hyperglycaemia in patients with acute coronary syndrome (REGULATE-ACS)

International journal of cardiology, 2023-01, Vol.370, p.26-34

2023

Volltextzugriff (PDF)

Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink

BMC medicine, 2018-07, Vol.16 (1), p.116-12, Article 116

2018

Volltextzugriff (PDF)

Inhibitors of the sodium-glucose transporter type 2 and new possibilities for managing vascular age in patients with type 2 diabetes mellitus

Medicinskij sovet, 2021-09 (12), p.228-236

2021

Volltextzugriff (PDF)

Dapagliflozin in the treatment of patients with heart failure with reduced left ventricular ejection fraction - a practical approach

Postępy w kardiologii interwencyjnej, 2021-06, Vol.17 (2), p.135-140

Nessler, Jadwiga

2021

Volltextzugriff (PDF)

The effect of Ramadan fasting on serum osmolality in diabetic patients

Journal of the Pakistan Medical Association, 2023-04, Vol.73 (4), p.767-770

2023

Volltextzugriff (PDF)

Sodium-glucose cotransporter-2 inhibitors protect against atrial fibrillation in patients with heart failure

Annals of palliative medicine, 2021-10, Vol.10 (10), p.10887-10895

2021

Volltextzugriff (PDF)

The role of sodium glucose cotransporter or glucagon-like peptide-1 receptor agonists in treating heart failure with preserved ejection fraction in patients with type 2 diabetes mellitus

Practica medicală (2006), 2024-03, Vol.19 (1), p.30-37

2024

Volltextzugriff (PDF)

Three Levels of Disease Modification with SGLT-2 Inhibitors: Holy Grail in Vasculopathy

RUHS journal of health sciences, 2023-07, Vol.7 (4)

2023

Volltextzugriff (PDF)

Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin

Diabetes, metabolic syndrome and obesity, 2019-12, Vol.12, p.2549-2557

2019

Volltextzugriff (PDF)

Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial

European heart journal, 2023-01, Vol.44 (1), p.41-50

2023

Volltextzugriff (PDF)

SGLT-2 inhibitors in heart failure: a literature review on mechanisms, efficacy and safety

Quality in Sport, 2024-07, Vol.15, p.52083

2024

Volltextzugriff (PDF)

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study

Clinical kidney journal, 2018-12, Vol.11 (6), p.749-761

2018

Volltextzugriff (PDF)

Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study

Journal of the American College of Cardiology, 2018-06, Vol.71 (23), p.2628-2639

2018

Volltextzugriff (PDF)

Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus

Circulation (New York, N.Y.), 2017-09, Vol.136 (12), p.1167-1169

2017

Volltextzugriff (PDF)

Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial

Circulation (New York, N.Y.), 2020-04, Vol.141 (15), p.1227-1234

2020

Volltextzugriff (PDF)

Sodium-glucose cotransporter-2 inhibitors: A treatment option for recurrent vasovagal syndrome?

Metabolism, clinical and experimental, 2022-12, Vol.137, p.155309-155309, Article 155309

2022

Volltextzugriff (PDF)

Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control

Frontiers in physiology, 2018-10, Vol.9, p.1514-1514

2018

Volltextzugriff (PDF)

Dapagliflozin exerts anti-inflammatory effects via inhibition of LPS-induced TLR-4 overexpression and NF-κB activation in human endothelial cells and differentiated macrophages

European journal of pharmacology, 2022-03, Vol.918, p.174715-174715, Article 174715

2022

Volltextzugriff (PDF)

Comparable COVID‐19 outcomes with current use of GLP‐1 receptor agonists, DPP‐4 inhibitors or SGLT‐2 inhibitors among patients with diabetes who tested positive for SARS‐CoV‐2

Diabetes, obesity & metabolism, 2021-06, Vol.23 (6), p.1397-1401

2021

Volltextzugriff (PDF)

Hyperglycemic DKA in a patient with type 2 diabetes mellitus on monotherapy with SGLT-2 inhibitor

Journal of clinical and translational endocrinology case reports, 2024-06, Vol.32, p.100166, Article 100166

2024

Volltextzugriff (PDF)

Effect of dapagliflozin on collectins and complement activation in plasma from patients with type 2 diabetes and albuminuria: Data from the DapKid cohort

Immunobiology (1979), 2024-05, Vol.229 (3), p.152797, Article 152797

2024

Volltextzugriff (PDF)

SGLT-2 Inhibitors: Are They a Promising Treatment Option in T2DM Patients with NAFLD?

Acta medica Lékarskí fakulty Univerzity Karlovy v Hradci Králove, 2017-01, Vol.60 (4), p.167-170

Patoulias, Dimitrios

2017

Volltextzugriff (PDF)

Drug Therapy in Obesity: A Review of Current and Emerging Treatments

Diabetes therapy, 2020-06, Vol.11 (6), p.1199-1216

2020

Volltextzugriff (PDF)

1 – 25 von 641

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(543)
Mit Volltextzugriff
(522)

Publikationsform

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(530)
Life Sciences & Biomedicine
(527)
Sglt-2 Inhibitors
(392)
Humans
(281)
Diabetes
(267)
Diabetes Mellitus
(199)
Endocrinology & Metabolism
(195)
Diabetes Mellitus, Type 2 - Drug Therapy
(193)
Glucose
(177)
Type 2 Diabetes
(170)
Sglt-2 Inhibitor
(163)
Sodium-Glucose Transporter 2 Inhibitors - Therapeutic Use
(128)
Heart Failure
(123)
Pharmacology & Pharmacy
(113)
Hypoglycemic Agents - Therapeutic Use
(109)
Cardiovascular System & Cardiology
(107)
Dapagliflozin
(97)
Clinical Trials
(94)
Cardiac & Cardiovascular Systems
(92)
Cardiovascular Disease
(89)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(11)

Menü

Weitere Dienste

Einstellungen

Long‐term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52‐week outcomes from the DEPICT‐1 and ‐2 studies

Potential mechanisms responsible for cardioprotective effects of sodium-glucose co-transporter 2 inhibitors

Real-world evaluation of glucose-lowering therapies and the use of weight-adjusted variable rate intravenous insulin infusion in the management of hyperglycaemia in patients with acute coronary syndrome (REGULATE-ACS)

Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink

Inhibitors of the sodium-glucose transporter type 2 and new possibilities for managing vascular age in patients with type 2 diabetes mellitus

Dapagliflozin in the treatment of patients with heart failure with reduced left ventricular ejection fraction - a practical approach

The effect of Ramadan fasting on serum osmolality in diabetic patients

Sodium-glucose cotransporter-2 inhibitors protect against atrial fibrillation in patients with heart failure

The role of sodium glucose cotransporter or glucagon-like peptide-1 receptor agonists in treating heart failure with preserved ejection fraction in patients with type 2 diabetes mellitus

Three Levels of Disease Modification with SGLT-2 Inhibitors: Holy Grail in Vasculopathy

Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin

Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial

SGLT-2 inhibitors in heart failure: a literature review on mechanisms, efficacy and safety

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study

Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study

Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus

Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial

Sodium-glucose cotransporter-2 inhibitors: A treatment option for recurrent vasovagal syndrome?

Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control

Dapagliflozin exerts anti-inflammatory effects via inhibition of LPS-induced TLR-4 overexpression and NF-κB activation in human endothelial cells and differentiated macrophages

Comparable COVID‐19 outcomes with current use of GLP‐1 receptor agonists, DPP‐4 inhibitors or SGLT‐2 inhibitors among patients with diabetes who tested positive for SARS‐CoV‐2

Hyperglycemic DKA in a patient with type 2 diabetes mellitus on monotherapy with SGLT-2 inhibitor

Effect of dapagliflozin on collectins and complement activation in plasma from patients with type 2 diabetes and albuminuria: Data from the DapKid cohort

SGLT-2 Inhibitors: Are They a Promising Treatment Option in T2DM Patients with NAFLD?

Drug Therapy in Obesity: A Review of Current and Emerging Treatments

Suchergebnisse filtern